Integrative neurochemistry and neurobiology of social recognition and behavior analyzed with respect to CD38-dependent brain oxytocin secretion

著者	Salmina Alla B., Lopatina Olga, Kuvacheva Natalia V., Higashida Haruhiro
journal or publication title	Current Topics in Medicinal Chemistry
volume	13
number	23
page range	2965-2977
year	2013-12-01
URL	http://hdl.handle.net/2297/36473

doi: <https://doi.org/10.2174/15680266113136660211>

**Integrative neurochemistry and neurobiology of social recognition and behavior
analyzed with respect to CD38-dependent brain oxytocin secretion**

Alla B. Salmina^{1,2}, Olga Lopatina² & Natalia V. Kuvacheva², Haruhiro Higashida^{1*}

¹Research Center for Child Mental Development, Kanazawa University, Kanazawa, Japan

²Department of Biochemistry, Medical, Pharmaceutical and Toxicological Chemistry,
Krasnoyarsk State Medical University, Krasnoyarsk, Russia

Keywords: CD38, oxytocin, social behavior

**Corresponding author: e-mail: haruhiro@med.kanazawa-u.ac.jp*

Correspondence:

Dr. Haruhiro Higashida

Research Center for Child Mental Development, Kanazawa University,

Takara-machi 13-1, Kanazawa, 920-8640, Japan

e-mail: haruhiro@med.kanazawa-u.ac.jp

Abstract:

This review summarizes the literature and our own data regarding the role of NAD⁺-glycohydrolase/CD38-controlled molecular mechanisms of hypothalamic and pituitary oxytocin secretion in social behavior regulation. Current approaches to the modulation of both CD38 expression and brain cell activity that represent prospective treatments for disorders associated with altered social behavior are discussed.

Catalytic properties of NAD⁺-glycohydrolase/CD38

NAD⁺ metabolism in brain cells is tightly coupled to their functional activity, viability, and the development of neuroplasticity [1, 2]. NAD⁺ release from brain cells corresponds to neuronal activity and might have biological significance. Recent data suggest that NAD⁺ may be a novel candidate neurotransmitter translating metabolic signals into changes in gene transcription via the CD38/NAD⁺/cyclic ADPR/Ca²⁺ pathway [3, 4, 5].

NAD⁺ acts as a substrate for NAD⁺-converting enzymes located outside or inside the cells. Among all the NAD⁺-degrading enzymes expressed in brain cells, including (poly(ADP-ribose) polymerase and ADP-ribosyltransferase (?)), NAD⁺-glycohydrolase/CD38 is in the focus of thorough investigations in last 20 years. Because its expression is modified in neuronal and glial cells associated with brain development, neurotransmitters action, and various pathophysiological conditions. This molecule has also been implicated in the regulation of intercellular communication, apoptosis, cell migration, and neurosecretion [5, 6, 7].

Two kinetic mechanisms are involved in enzymatic activities of CD38: cyclization of NAD⁺ into cyclic ADP-ribose (cADPR) followed by its hydrolysis to ADP-ribose (ADPR); conversion of NADP⁺ in the presence of nicotinic acid into nicotinic acid adenine dinucleotide phosphate (NAADP). The most studied enzymatic activity of CD38 in various tissues is the formation of cADPR with calcium-mobilizing activity and of ADPR that may be further used for mon- or poly-ADP-ribosylation of functional proteins [8, 9, 10, 11, 12, 13]. Formation of cADPR leads to Ca²⁺ mobilization from intracellular Ca²⁺ stores in the inositol-1,4,5-trisphosphate-sensitive and ryanodine-dependent endoplasmic reticulum, while NAADP acts at the different set of Ca²⁺ stores [7, 14].

In addition, CD38 may act as a receptor interacting with the non-substrate ligand (i.e. CD31) on the cell surface [15, 16, 17]. In certain cases, ligand-induced CD38 internalization occurs, allowing the production of intracellular cADPR. Recently, it has been shown that the catalytic domain of CD38 may be oriented either to the cytosol or the extracellular space [18,19]. The form of CD38 that is constructed as a type III protein (in which the C-terminal catalytic domain and the N-terminal tail would face the cytoplasm and the outside of the cell, respectively) is catalytically active in increasing cellular cADPR concentrations. For long time it has been known that CD38 is found in intracellular organelles in which cases CD38 is in the type III orientation. Therefore, a flipping mechanism could affect CD38 signaling activity [18]. Ratio of plasma membrane and intracellular CD38 may depend on the cell type and function. Associated molecules (i.e. Cx43) may act as nucleotide transporting channels providing access of NAD⁺ to CD38 [UH Kim? Or De Flora?]. It is believed that CD38 acting either at the cell

1 surface or inside the cell may serve as a redox-sensor or as a NAD⁺-sensor adjusting cell
2 metabolic activity to the current needs [19, 20]. Thus, catalytic activity of CD38 might be tightly
3 coupled to other NAD⁺-consuming or NAD⁺-dependent processes in cells including DNA
4 replication and repair, epigenetic regulation, posttranslational modification of proteins, and
5 energy metabolism etc.

6 *CD38 expression and brain cell activity*

8 In brain cells, CD38 is expressed on the surface of the plasma membrane and in various
9 intracellular compartments, including mitochondria, the endoplasmic reticulum ribosomes, and
10 the nucleus. Synaptic vesicles have been found to be immunopositive for CD38 [21]. In the
11 central nervous system, CD38 is expressed in various brain regions, including the cortex and
12 limbic system, and the pituitary [15]. CD38 expression occurs during an early period of
13 embryonic development [16, 22] and during the postnatal period of brain development [5]. CD38
14 expression in neurons and glia can be affected by multiple factors; however, it is generally
15 assumed that neurons, astroglia and microglia express significant levels of CD38, especially
16 when stimulated with neurotransmitters (for neurons and astrocytes) or pro-inflammatory
17 molecules (for microglia). Intracellular localization may also differ in these cell types: neurons
18 express CD38 in the cytosol, while astrocytes and microglial cells express CD38 oriented
19 towards the extracellular space. No clear information regarding CD38 expression in
20 oligodendrocytes or NSCs has been published.

21 In various mammalian cells, CD38 expression is regulated by retinoic acid, thyroid
22 hormones, estrogens and other hormones, glutamate, interleukins, and TNF- α [17]. Receptor-
23 regulated activation of NAD⁺-glycohydrolase/CD38 activity in the central nervous system is
24 well-described [23, 24]. Excitable cells may depend on other types of CD38 biological activity
25 including redox sensing [25] and NAD⁺-sensing [20].

26 It should be noted that brain cells have a vast spectrum of enzymes involved in
27 maintaining NAD⁺ homeostasis [26]. In 2006, Aksoy et al. proposed a key role of CD38 in the
28 regulation of intracellular levels of NAD⁺ and of other related molecules in various mammalian
29 cells including brain cells [27]. This hypothesis was later verified [28]. Therefore, CD38 activity
30 may affect the following NAD⁺-converting enzymes and molecular targets of cyclic ADP-ribose,
31 which are responsible for the regulation of pivotal cellular functions, which are described below:

32 a) Sirtuins (NAD⁺-dependent histone deacetylases) control synaptic plasticity,
33 memory consolidation, brain aging, and neurodegeneration [29,30,31]. CD38 may regulate
34 NAD⁺-bioavailability for sirtuins in the cell nucleus [32]. *Cd38*^{-/-} mice exhibit altered metabolic

1 circadian rhythms associated with behavioral abnormalities [33], which are likely due to elevated
2 levels of intracellular NAD^+ ;

3 b) Poly(ADP-ribose)polymerase (PARP) exhibits the strongest known NAD^+ -
4 consuming ability among all other intracellular NAD^+ -converting enzymes. PARP acts as a
5 competitor to sirtuins in accessing the intracellular NAD^+ pool [34]. Little is known regarding the
6 possible roles of CD38 in the functional connection between these two types of enzymes;
7 however, one may propose that in normal physiological conditions, CD38 and sirtuins may play
8 a dominant role in the regulation of intracellular NAD^+ levels, while in pathological contexts (i.e.,
9 oxidative stress) NAD^+ is mainly consumed by PARP;

10 c) The molecular targets of cyclic ADP-ribose include type 2 and 3 ryanodine
11 receptors, which use cyclic ADPR for calcium release from intracellular stores [35, 36]. TRPM
12 ion channels regulate Ca^{2+} influx and act as oxidative stress sensors [37, 38] that are controlled
13 by cyclic ADPR [39]. The latter mechanism was previously demonstrated in oxytocin-mediated
14 Ca^{2+} -dependent secretion in NG108-15 cells [40];

15 d) The activity of P2X7 purinergic receptors is involved in the transmembrane
16 transfer of ions and nucleotides by two processes: i) NADH transport across the astrocyte plasma
17 membrane, and, ii) NAD^+ /cADPR conversion to P2X7-targeting diadenosine homodinucleotides.
18 Bifunctional P2X7 receptors for extracellular ATP mediate NADH transport across the
19 astrocyte's plasma membrane. P2X7 receptors form either cation-selective channels or
20 nonselective pores with large conductance, depending on the levels of activation. However, the
21 regulatory mechanism for the channel opening and pore formation of P2X7 receptors are not
22 well understood [41].

23 NAD^+ levels could be regulated by the CD38-mediated production of cyclic ADPR
24 followed by its conversion to diadenosine homonucleotides (isomers of diadenosine
25 diphosphate) via Ca^{2+} -mobilizing activity [42]. In addition, extracellular NAD^+ can act as a
26 substrate for ecto-ADP- ribosyltransferase at the plasma membrane. Thus, possibly, P2X7
27 receptors can be ADP-ribosylated [43], suggesting other cellular applications for CD38-mediated
28 production of ADP-ribose. P2X7 receptors are functionally coupled to pannexin-1, and their
29 interactions play an important role in controlling membrane permeability. It is generally believed
30 that the cellular responses triggered by P2X7 depend on the structure of signaling complex
31 formed by P2X7 and its associated molecules, including pannexin-1 [44]. Pannexin-1 acts as an
32 ATP-permeant channel and is expressed in neurons, astrocytes, and pituitary cells [45]. This
33 result suggests that there is a physiological role of pannexins' tight coupling to P2X7 receptors,
34 which is regulated by cADPR in the brain. This action is likely supported by the activity of

1 connexins that provide regulated transport of NAD⁺, ATP, and neurotransmitters [46]. Recent
2 data regarding treatments targeting P2X7 receptors to correct autism-like behavioral
3 abnormalities in an animal model have indirectly confirmed this action [47].

4
5 *Alterations in social behavior due to neurosecretory dysfunction*
6 *in the hypothalamic-pituitary-limbic system*

7 Neuropeptides, neurotransmitters and multiple steroid hormones play a central role in
8 regulating social behavior in mammals. Several behavior-regulating neuropeptides have been
9 described [48]; in recent decades, much attention has been paid to oxytocin (OT) and arginine
10 vasopressin (AVP) in the context of social recognition, social memory, mood regulation,
11 aggression, and social behavior [49, 50]. The effects of these peptides are important in a variety
12 of species and are moderated by receptor densities in the brain and the efficacy of neurosecretory
13 events of the hypothalamus and pituitary [51]. The majority of OT and AVP biological effects in
14 the central nervous system are concentrated in limbic regions (particularly, in the amygdala and
15 the hippocampus), which are implicated in social affiliation, cognition, emotions, motivation,
16 and sexual behavior.

17 Casual relationships between OT and AVP and social behavior have been intensively
18 studied in experimental models and in humans. The results of these studies suggest that OT acts
19 as a regulator of responses to social stress and facilitator of approach behavior, while AVP is
20 mainly considered to be a mediator of anxiogenic action and modulator of male-typical social
21 behaviors, including aggression and pair-bond formation [48, 49]. However, such functional
22 differentiation is relative. At present, OT is implicated in the regulation of social recognition,
23 memory and bonding, adjustment of the hypothalamic-pituitary-adrenal (HPA) axis under
24 stressful conditions, maternal behavior (including maternal aggression), male and female sexual
25 behaviors, empathy-based group formation, paternal and maternal care, feelings of attachment,
26 development of more constructive behavioral approaches, and the establishment of social
27 distance between males and females [50-60]. Balanced activity of both brain neuropeptide
28 systems is important for appropriate emotional behavior [61]. In the coordination of parental care,
29 mothers show greater amygdala activation and correlations between amygdala responses and OT,
30 while fathers exhibit greater activation in social-cognitive circuits that are correlated with AVP
31 [62].

32 OT attenuates stress-induced HPA activity and may produce anti-stress effects. It is
33 suggested that the adaptation mechanism to chronic stress may involve up-regulation of oxytocin
34 expression in the hypothalamus [63]. Chronic isolation stress results in increased plasma OT

1 levels and OTR mRNA in the hypothalamus in females, but not in males [64]. Central OT, but
2 not AVP, attenuates both stress-induced neuroendocrine and molecular HPA axis responses and
3 the dorsal hippocampus and paraventricular nuclei (PVN) constitute an OT-sensitive forebrain
4 stress circuit [65]. Sexually dimorphic mechanisms of action for OT and AVP may underlie
5 anxiety and repetitive behaviors commonly observed in children with ASD [66].

6 Different patterns of intracerebral release and action of OT may influence its regulatory
7 activity in social behavior to a greater extent than do differences in OT receptor (OTR) levels in
8 the brain. In the brain, OT is produced and released by magnocellular neurons of the PVN and
9 supraoptic nuclei (SON) of the hypothalamus. In hypothalamic nuclei, OT gene expression and
10 OT release is stimulated by hypertonic saline, parturition, suckling in lactating females, GABA,
11 NO, glutamate, ATP, norepinephrine, IL-1 β , estradiol and neurosteroids, maternal behavior,
12 prostaglandins, angiotensin II, dopamine, and various stressors [67-69]. Some of these factors act
13 in an age-dependent manner: more OT can be released from the SON in young rodents compared
14 to older individuals [70].

15 OT in neurosecretory cells of the PVN and SON are packaged into specialized organelles:
16 large dense-cored vesicles are transported via the microtubule cytoskeleton to the secretory sites
17 of axon terminals or dendrites. The involvement of SNARE proteins in OT release remains
18 controversial. The neurohypophyseal nerve terminals possess at least two functionally distinct
19 and acutely releasable secretory granule pools that differ in size and Ca²⁺ sensitivity: 1) the
20 immediately releasable pool and 2) the readily releasable pool (Ca²⁺-dependent) [71].

21 OT is released in the brain from magnocellular neuronal dendrites in very large
22 quantities; this type of release may be regulated independently from axonal secretion [72]. OT
23 and AVP release are closely correlated with intracellular Ca²⁺ dynamics, which are mainly
24 controlled by intracellular Ca²⁺ stores (endoplasmic reticulum) [73] and cytoskeletal remodeling
25 [74]. Both types of OT secretion (dendritic and axonal) are triggered by increases in intracellular
26 Ca²⁺ levels. However, dendritic release, but not axonal release, can be primed for further
27 activity-dependent release by mobilizing Ca²⁺ from intracellular stores [75]. Recently, different
28 compositions of voltage-gated Ca²⁺ channels (VGCC) were found in the two types of
29 hypothalamic neurosecretory terminals: L, N, and Q in AVP terminals vs. L, N, and R in OT
30 terminals. However, these channels do not differ greatly in relation to specific aspects of their
31 release mechanisms. The only difference observed was attributed to the expression of purinergic
32 receptors that affect VGCC functioning in these cells [76].

33 We recently found a novel CD38-dependent mechanism of intracellular Ca²⁺
34 mobilization, which plays a key role in OT release from the soma and axonal terminals of

hypothalamic neurons. This mechanism was related to profound changes in various social behaviors and did not play a role in AVP secretion (Figure 1). There is growing evidence that OT may be related to autism [77 - 80]. Defective OT and AVP function have been reported to play a role in the development of autism spectrum disorders (ASD) [81, 82]; genetic and epigenetic changes in OTR as well as changes in plasma OT levels have been discovered in patients with ASD [83].

Data from our laboratories demonstrate that impairment of the CD38/cADP-ribose system in the hypothalamo-neurohypophyseal system results in changes in OT secretion, but not AVP secretion, in humans [84] and in mice [85, 86, 87]. Impairments of this system have also been associated with abnormal social behavior in mice [85, 86]; this suggests new clues to understanding the pathogenesis of neurodevelopmental disorders [11, 30]. CD38 is highly expressed in the rodent and human hypothalamus [88]. Retinoic acid, an inducer of CD38 expression in various cell types, was recently discovered in the rat hypothalamus (PVN) [89], and retinoic acid synthesizing enzyme retinaldehyde dehydrogenase 1 is expressed in the hypothalamus. This is analogous to results reported by Stoney et al. [90], who demonstrated that increasing hypothalamic retinoic acid levels are sufficient to up-regulate various responsive genes: we can propose that retinoic acid metabolizing enzymatic machinery in the hypothalamus could provide enough retinoic acid to up-regulate CD38 expression. However, this must be confirmed experimentally.

CD38-controlled mechanisms revealed in Cd38 knockout mice

In CD38 gene knockout mice [91], we demonstrated that CD38-dependent cADPR- and NAADP-sensitive intracellular Ca^{2+} mobilization plays a key role in OT release from the soma and axonal terminals of hypothalamic neurons and exhibits profound modulation of social behaviors. Altered Ca^{2+} signaling observed in *Cd38*^{-/-} mice was correlated with reduced ADP-ribosyl cyclase activity in the examined brain regions. Immunohistochemical analysis also demonstrated reduced CD38 immunoreactivity in hypothalamic periventricular regions. Plasma and cerebrospinal fluid (CSF) OT levels were lower in *Cd38*^{-/-} mice than in *Cd38*^{+/+} mice, and OT was extensively packaged in the hypothalamus and pituitary in *Cd38*^{-/-} mice due to alterations in the Ca^{2+} -mediated release of OT-containing vesicles [85, 92]. We found that *Cd38*^{-/-} mice exhibited altered communicative behaviors that were similar to those observed in *Oxt*^{-/-} and *Oxtr*^{-/-} mice. In these mice, both the injection of OT and the expression of CD38 were able to restore the observed social memory deficits [88].

1 Interestingly, CD38-controlled mechanisms of central OT release are clearly dependent
2 on reproductive experience in female mice, and in male mice, associations between peripheral
3 OT levels and parenting and paternal care have been described [93]. In support of our
4 experimental findings, reproductive experience improves parental behavior in *Cd38*^{-/-} male mice
5 (even to a lower extent than in *Cd38*^{-/-} females), thus, experience-mediated remodeling of the
6 neuroendocrine system and neurosecretory events may be controlled, at least in part, by the
7 CD38/cyclic ADPR system.

8 OT itself can elicit dendritic peptide release without increasing neuronal electrical
9 activity [72]. The activation of peptide receptors on the dendrites or soma elevates intracellular
10 Ca^{2+} concentrations and triggers exocytosis. Once dendritic peptide release is triggered, feedback
11 allows for self-sustaining and long-lasting release to occur. We found that CD38 is also involved
12 into the autoregulation of OT secretion in the hypothalamus and pituitary of rodents [87]. Our
13 data on parental behavior, social recognition, and the findings of our in vitro study have
14 indicated that social experiences lead to consecutive stimulation of OT neurons, the activation of
15 CD38/ADP-ribosyl cyclase activity, Ca^{2+} mobilization from intracellular stores, OT release, and
16 the activation of positive feedback in PKC- and cADPR-dependent manners [88, 94].

17 In accordance with our experimental findings in mice, a mutation in the CD38 gene is
18 found to be associated with lower plasma OT levels in humans [84]. Similar allele frequencies
19 for the genotyped SNPs in men and women are comparable. Additionally, similar correlations
20 between plasma OT, CD38, and human OTR SNP variants and parenting behavior have been
21 observed between mothers and fathers [95]. Positive feedback of OT-induced OT release has
22 been previously confirmed in humans [96, 97].

23 Other NAD^{+} -dependent mechanisms may also be involved in the regulation of OT and
24 AVP-producing neurons, including differential expression of NAD^{+} -dependent histone
25 deacetylases in monoaminergic and neuropeptidergic neurons [98].

26 Specific patterns of OTR expression in hypothesized social brain regions correlate to
27 functional characteristics of these areas obtained using fMRI [99, 100]. The role of OT in the
28 regulation of the limbic system as a major social brain region has been confirmed in numerous
29 experimental studies: corticosteroids regulate binding of OT to OTR in hippocampus [101], and
30 this mechanism is responsible for OT-controlled behavioral hippocampal responses [102]; OT is
31 secreted in the hippocampus during complex behavioral reactions [103]; activation of OTR in the
32 medial amygdala is required for social recognition in mice [104]; and the positive effects of OT
33 in socially-stimulated learning depends on amygdala functional activity in humans [105]. In the
34 hypothalamic nuclei, OT is mainly released from dendrites; in the pituitary and the hippocampus,

OT is released from axonal terminals [106]. Data regarding local OT release in the amygdala remains controversial [107, 108]. Abnormal amygdaloid structure has been implicated in the pathophysiology of ASD and depression; therefore, OT release and action in the amygdala may be of interest in integrative neurochemistry and the neurobiology of social behavior.

Differences in the molecular mechanisms controlling OT and AVP release in the hypothalamus and pituitary (CD38 controls OT, but not AVP release) may have implications considering OT and AVP release and action in the amygdala. CD38 is expressed in the amygdala; however, expression levels are significantly lower in the amygdala than in the hypothalamus [109], and cyclic ADP-ribose-controlled TRPM2 channels are also expressed in amygdala [110]. The activation of amygdala AVP and OT receptors have opposing effects on fear and anxiety-related behaviors: AVP enhances aggressiveness, anxiety, and stress levels and the consolidation of fearful memories, while OT decreases anxiety and stress and facilitates social encounters, maternal care, and the extinction of conditioned avoidance behavior. It was previously shown that OT and AVP stimulate different populations of neurons in the central amygdala, thus modulating the integration limbic and cortical information [111]. This result strongly supports OT and AVP act as antagonists in the regulation of social behavior: OR reduces anxiety and stress-stimulated behavioral responses, while AVP mediates defensive behavior.

Postulated roles of CD38 in the amygdala

The amygdala is highly connected to other areas of the brain. Hypothalamic OT, hypocretin and melanin-concentrating hormone neurons have many projections to the central amygdala, thereby regulating region-associated behaviors and personality traits [108, 112, 113]. Estrogens have been shown to regulate OTR expression in this part of the limbic system. OT effects on amygdala are numerous: OT can facilitate amygdala-dependent, socially reinforced learning and emotional empathy in humans [105] and can modulate the expression of evaluative conditioning for socially relevant faces via influences on the amygdala and fusiform gyrus. The latter effect may explain prosocial activity of OT [114].

Amygdala-hypothalamus interconnection is mediated by OT-dependent mechanisms, and establishing medial amygdala-controlled inter-male aggressive behavior is associated with immediate early gene expression in OT neurons located in specific brain regions [115]. OT acts in the medial amygdala during an initial exposure to facilitate social recognition; OT given before, but not after, an initial encounter restores social recognition in *Oxt*^{-/-} mice [104]. It is

well-known that the medial amygdala modulates female social recognition. Antisense oligonucleotides specific for OTR administered into the medial amygdala several days prior to testing has been shown to significantly reduce social recognition in females. This indicates that OTR expression in this region is necessary for proper social recognition [116]. Furthermore, a model of social cognitive dysfunction was recently proposed that comprises abnormalities in oxytocinergic and dopaminergic signaling in the amygdala, resulting in impaired emotional salience processing and consequent social cognitive deficits in schizophrenia [117].

Many authors believe that OT primarily reduces amygdala activity [118], and certain studies indicate that OT is able to increase amygdala activation for pleasant stimuli. Thus, the amygdala might be a key structure mediating not only the positive influence of social feedback in general but also the specific influence of OT on socially-reinforced learning [119]. OT can facilitate amygdala-dependent emotional empathy in humans [105]. In stressful conditions, the oxytocinergic system of the amygdala is significantly activated in stress-coping strategies [120]. OTR polymorphism affects amygdala volume, most likely due to greater cortisol exposure [121]. OT and AVP in the medial amygdala mediate approach and avoidance behavior; however, the manner in which these behaviors are mediated differ significantly [122].

Alterations of central OT release and action in the deregulation of brain development

Autism is a neurodevelopmental disorder characterized by prominent alterations in social interactions, communication, and the appearance of stereotyped repetitive behaviors with restricted interests [123, 124]. Defects in neurotransmitters release and reception, synaptic proteins, mitochondrial function, signal transduction pathways, and innate immune responses have been implicated in the complex pathogenesis of autism.

Neurodevelopmental disorders have origins in early life, and more classical conceptions have recently been replaced with the theory of complex interactions between genes and the environment, resulting in the phenomenon of early life programming [125]. Early life stresses (including prenatal exposure to toxic or immunogenic agents, perinatal stress itself), nutritional status at the perinatal period, and changes in regulatory neuroendocrine networks could result in postponed alterations in cognition and social behavior. NAD⁺ metabolism in brain cells has recently been attributed to the development of this phenomenon, with a special focus on NAD⁺-dependent histone deacetylases as epigenetic regulators [126] or NAD⁺-converting enzymes affecting neuronal fate [127].

1 Little, and occasionally controversial, information is available regarding development-
2 associated changes in brain expression of CD38 and its associated molecules in relation to
3 behavioral alterations occurring later in the life. Ceni et al. [128] found dramatic elevations of
4 ADP-ribosyl cyclase activity in the adult rodent brain compared to that observed on postnatal
5 day 1. The same team later revealed that *Cd38*^{-/-} mouse brains have high intracellular ADP-
6 ribosyl cyclase activity and that higher levels of activity are detected in synaptosomes purified
7 from neonates than in those of adult animals. These authors found this to be consistent with the
8 observation that endogenous brain cyclic ADPR concentrations, which are definitively not
9 related to the presence of the CD38 protein, are higher in the developing brain and decline in
10 adult tissue over time [16]. We have demonstrated dynamic changes in CD38 expression in the
11 cortex of rodents from postnatal day 1 to postnatal day 48 and that such changes were correlated
12 with NAD⁺ levels and apoptosis of brain cells [22, 129].

13 Birth-related surges in maternal OT may regulate synchronization of children's
14 hippocampal neurons and may be important for the transitions from prenatal to postnatal life.
15 Thus, this mechanism may induce long-lasting behavioral endophenotypes [130]. The OT system
16 continues to mature after birth and may be especially sensitive to the factors affecting brain
17 development during the perinatal and neonatal periods. Hypothalamo-neurohypophysial neurons
18 secreting OT and AVP migrate early in the development of the PVN and SON and send their
19 axons to the neurohypophysis. The neurogenesis of OT- and AVP-producing neurons continues
20 in the adult hypothalamus and is stimulated by conditions requiring higher neuropeptide levels
21 for adequate neuroendocrine responses [131, 132].

22 Reduced OT plasma concentrations mark not only ASD but also borderline personality
23 disorder, which is believed to be closely related to traumatic childhood experiences and is
24 characterized by (para)suicidal behaviors as well as aggressive outbursts. However, OT-
25 mediated links between early life stress and the development of borderline personality disorder
26 are not confirmed [133].

27 Generally, social behavior may be viewed as a situation associated with dramatic changes
28 in the neurogenesis of various brain regions (i.e., olfactory bulbs, hippocampus, amygdala,
29 hypothalamus, subventricular zone, cortex, and nucleus accumbens) [134]. This has been clearly
30 demonstrated in parental behavior [135], paternal recognition of offspring [136], and social
31 interactions of females with male, but not female conspecifics [137]. It is interesting that
32 maternal behavior is not affected when neurogenesis is impaired in the olfactory system but
33 spared in the hippocampus [138].

OT itself can powerfully stimulate proliferation of neural progenitors in the adult hippocampus [139], but whether the same activity occurs with respect to neurogenesis in the hypothalamus is unknown. OT, but not AVP, stimulates adult neurogenesis in the hippocampus of rats subjected to stress [140]. Due to its action in cytoskeletal structure, OT was proposed to act as a growth factor for neurons [141].

Experiences in the first few days of the life are mediated by sexually dimorphic changes in OT and OTR levels. This is highly sensitive to different animal handling regimens and provides a basis for establishing behavioral reactions occurring within the phenomenon of early life programming [142]. Early life chronic social stress has long-term effects on maternal care (due to changes in OT and prolactin levels), leading to decreased nursing efficiency in adult dams [143]. This may result in the formation of “*circulus vitiosus*” in the pathogenesis of neurodevelopmental disorders: when dams are stressed in their early life, they will provide less maternal care and thus provoke early life stress in their offspring. Neonatal exposure to OT may influence receptor expression for neuropeptides of transmitters that have been implicated in social behavior, and such effects are region-specific and sexually dimorphic [144, 145].

Short-term maternal separation (a widely used experimental model of early life stress) results in significantly lower OT levels in the rat hypothalamus and amygdala and elevated levels in the pituitary gland in juvenile rats, while in adult rats hypothalamic expression of OT is not changed. OT expression was found to be the most sensitive parameter in maternal separation-induced neurochemical alterations [146], and the AVP system was not affected by maternal separation. As expected, early interactions with the mother and peers resulted in elevated levels of OTR in the amygdala and enhanced adult affiliation behavior [147].

A recently proposed theory states that OT stimulates prosocial behavior by facilitating the connectivity between different brain regions (i.e., posterior cingulate cortex, cerebellum, postcentral gyrus) and that this effect is modulated by the experience of maternal love withdrawal [148]. A well designed study by Feldman [149] clearly demonstrated that OT functioning is transferred from parent to child through patterns of parental care: children’s social contact with peers is associated with OT plasma levels, the expression of the OT gene in the mother, and the quality of social contact between the mother and child. Additionally, low child OT levels can be predicted by the interaction of maternal high-risk CD38 alleles and diminished maternal care in infancy.

Extremely limited information exists regarding the changes in the OT system that are associated with aging. Aging affects neurocognitive and socio-emotional processes, which are likely due to alterations in OT release and signaling in the amygdala [150].

***Current approaches to pharmacological modulation of CD38 expression
and activity in mammalian cells***

The only existing pathogenetically proven pharmacological strategy by which to improve the CD38-controlled behaviors observed in ASD is the application of intranasal OT [151, 152]. However, the data are conflicting: numerous studies report positive results, but one study of intranasal OT administration in early life found that it led to the development of aggressive behaviors [153]. Thus, OT is not effective for all patients but may be beneficial for specific individuals and/or conditions [154, 155].

Deciphering the molecular mechanisms of central OT release provides novel approaches to treat ASD with high efficacy (Figure 2). Pharmacological modulation of CD38 expression and activity could theoretically be achieved via cADPR and its analogs. However, the clinical utility of cADPR as a pharmacological tool is limited by the rapid hydrolysis of this metabolite in the cells, therefore much attention is paid to the prospects for using various modulators of ryanodine receptors activity (caffeine, ryanodine, procaine, ruthenium red), FKBP ligands, and NAD⁺-glycohydrolase inhibitors.

Among all of the cyclic ADPR antagonistic derivatives, 8-amino-cADPR is the most potent antagonist and can block Ca²⁺ release-inducing cADPR activity in the nanomolar range [156]. Wagner et al. [157] produced cyclization of the dinucleotide of the nicotinamide 8-bromohypoxanthine at the nitrogen 1-position to yield cyclic 8-bromo-inosine diphosphoribose. Similarly, Gu et al. [158] synthesized N1-[(5"-O-Phosphorylethoxy)methyl]-5'-O-phosphorylinosine 5',5"-cyclic pyrophosphate (cIDPRE) and the 8-substituted derivatives 8-azido-, and 8-amino-cIDPRE as membrane-permeable mimics of cyclic ADPR. Cyclic aristeromycin diphosphate ribose, which contains oxygen in the ribosyl ring of the adenine ribose that can be replaced by carbon, is highly resistant to hydrolysis by cADPR hydrolase. It is thereby able to prolong the physiological action of cyclic ADPR; the same result could be achieved by converting the 7-nitrogen of the adenine ring to carbon, as in 7-deaza-cADPR [159]. Among analogs of cyclic ADPR, adenosine diphospho-carbocyclic-ribose significantly induces Ca²⁺ release, whereas cyclic aristeromycin diphosphoribose is slightly more active than the endogenous cyclic adenosine diphosphoribose. Shuto et al. [160, 161] have described derivatives of cyclic ADP-carbocyclic-ribose and their respective biological activity as well as the structure-activity relationships for selective analogs of cADPR.

Inhibition of CD38 activity can be achieved by various approaches. Nicotinamide 2'-deoxyriboside and 5-methylnicotinamide 2'-deoxyriboside can affect the formation of common covalent intermediates in the soluble domain of CD38. This domain is the site of NAD⁺ conversion to cADPR and further to ADPR [162]. Carbocyclic NAD⁺ analogs, in which 2,3-dihydroxycyclopentane methanol replaces the β -D-ribonucleotide ring of the nicotinamide riboside moiety of NAD⁺ (i.e., carbo-NAD⁺ and pseudocarbo-NAD⁺), are resistant to enzymatic cleavage of the pyridinium-carbon bond. These analogs also act as NAD⁺-glycohydrolase inhibitors; the same activity has been reported for arabinosyl-NAD⁺ and 2-fluoroarabinosyl-NAD⁺ [163]. Nicotinamide acts as a strong but non-specific inhibitor of NAD⁺-consuming enzymes. Small-molecule inhibitors (4,4'-dihydroazobenzene and 2,2'-dihydroazobenzene) have been shown to be effective suppressors of ADPR-cyclase [164]. Catalysis-based inhibitors of CD38 have been previously synthesized (arabinosyl-2'-fluoro-2'-deoxynicotinamide mononucleotide, etc.) [165]. One study reported that CD38 activity can be inhibited by micromolar concentrations of flavonoids (luteolinidin, kuromanin, luteolin) [166]. Novel approaches to manipulate CD38-mediated cADPR metabolism in vivo were recently proposed [167].

The group headed by Lee [168] has tested novel inhibitors of CD38 (N-substituted nicotinamide derivatives), and demonstrated that 1-(|2-(4-phenoxy-phenoxy)ethoxy|methyl)-3-(aminocarbonyl)-pyridinium chloride is highly potent; its nicotinamide portion binds to CD38 in a manner that is identical to that exhibited by NAD⁺. The authors cite that replacement of highly charged moieties of NAD⁺ with aromatic groups provides membrane permeability.

In contrast to CD38 inhibitors, stimulation of CD38 expression and increased CD38 activity can be attained with very few compounds. Retinoic acid has been shown to induce high levels of CD38 antigen expression in leukemia cells due to the activation of CD38 gene transcription [169]. Retinoic acid can also modulate CD38 expression in the rat brain after perinatal hypoxic-ischemic injury [156]. It may also modulate CD38 expression in lymphocytes obtained from patients with ASD [170]. However, the potential mechanisms that underlie up-regulation of CD38 expression in brain cells are not well studied [171]. It is interesting that alterations in the expression of the *Rai* gene (encoding for retinoic acid-induced transcription factor) are associated with neurodevelopmental disorders [172, 173], including ASD [174]. Chronic administration of retinoic acid results in abnormal behavior (decreased exploratory activity and elevated anxiety), most likely due to hyper-activation of the HPA axis [175]. Considering the important role of astrocytes as a source of endogenous brain retinoic acid that

affects neuronal proliferation and differentiation [176], the existing data provide a novel approach to manipulate CD38 activity in the brain under normal and pathological conditions.

Recently, sildenafil was reported to induce OT release from the pituitary [177], but this effect is mediated through modulation of phosphodiesterase activity and has no direct relationship to Ca^{2+} -dependent OT release.

Conclusion

A vast volume of recent data indicate that CD38-controlled homeostasis of NAD^+ and CD38-catalyzed cADPR formation are the important components of signal transduction pathways implicated in the regulation of pivotal brain cell functions (intercellular communication, excitability, proliferation, differentiation, migration, apoptosis) and neuroplasticity, in general. It is known that CD38 expression and activity in the brain are frequently altered by impaired interaction between neurons and glial cells at the sites of acute and/or chronic neurodegeneration, which may lead to pathological conditions during brain development and neuroinflammation [5, 7, 129, 178, 179, 180]. Furthermore, our recent findings regarding CD38-controlled neurosecretory activity of hypothalamic and pituitary cells [40, 92, 181, 182] open a new chapter in elucidating the role of CD38 in integrative brain functions and provide novel approaches to identify molecular targets for the pharmacological treatment of disorders associated with social behavioral alterations.

- 1 **List of abbreviations**
- 2 ADPR – adenosine diphosphate ribose
- 3 ASD – autism spectrum disorder
- 4 ATP - adenosine triphosphate
- 5 AVP – arginine vasopressin
- 6 cADPR – cyclic adenosine diphosphate ribose
- 7 CD38 – NAD⁺-glycohydrolase/CD38
- 8 NAD⁺ - nicotinamide adenine dinucleotide
- 9 NAADP - nicotinic acid adenine dinucleotide phosphate
- 10 NADH – nicotinamide adenine dinucleotide reduced
- 11 OT - oxytocin
- 12 OTR – oxytocin receptor
- 13 P2X7 – purinergic receptor 7
- 14 PARP – poly(adenosine diphosphate ribose)polymerase
- 15 PVN – paraventricular nucleus
- 16 RyR – ryanodine receptor
- 17 SNARE – soluble NSF attachment receptor
- 18 SON – supraoptic nucleus
- 19 TNF α – tumor necrosis factor α
- 20 TRPM – transient receptor potential cation channel, subfamily M, member 2
- 21 VGCC – voltage-gated calcium channel
- 22
- 23
- 24
- 25

1 **Acknowledgements**

2 A.B.S., O.L., and N.V. K. have been supported in part by the grant of the Ministry of Education and Science of
3 Russian Federation, Federal Program “Scientific and pedagogical specialists...” (project N 8061, 2012-2013).

4

5

References

1. Nikiforov, A.; Dölle, C.; Niere, M.; Ziegler, M. Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation. *J. Biol. Chem.*, **2011**, 286(24), 21767-21778.
2. Ying, W. NAD⁺ and NADH in brain functions, brain diseases and brain aging. *Front. Biosci.*, **2007**, 12, 1863-1888.
3. Durnin, L.; Dai, Y.; Aiba, I.; Shuttleworth, C.W.; Yamboliev, I.A.; Mutafova-Yambolieva, V.N. Release, neuronal effects and removal of extracellular β -nicotinamide adenine dinucleotide (β -NAD⁺) in the rat brain. *Eur. J. Neurosci.*, **2012**, 35, 423-435.
4. Higashida, H.; Salmina, A.B.; Olovyannikova, R.Y.; Hashii, M.; Yokoyama, S.; Koizumi, K.; Jin, D.; Liu, H.X.; Lopatina, O.; Amina, S.; Islam, M.S.; Huang, J.J.; Noda, M. Cyclic ADP-ribose as a universal calcium signal molecule in the nervous system. *Neurochem. Int.*, **2007**, 51, 192-199.
5. Salmina, A.B.; Lopatina, O.; Ekimova, M.V.; Mikhutkina, S.V.; Higashida, H. CD38/cyclic ADP-ribose system: a new player for oxytocin secretion and regulation of social behaviour. *J. Neuroendocrinol.*, **2010**, 22, 380-392.
6. Salmina, A.B. Neuron-glia interactions as therapeutic targets in neurodegeneration. *J. Alzheimers Dis.*, **2009**, 16, 485-502.
7. Salmina, A.B.; Inzhutova, A.I.; Morgun, A.V.; Okuneva, O.S.; Malinovskaia, N.A.; Lopatina, O.L.; Petrova, M.M.; Taranushenko, T.E.; Fursov, A.A.; Kuvacheva, N.V. NAD⁺-converting enzymes in neuronal and glial cells: CD38 as a novel target for neuroprotection. *Vestn Ross Akad. Med. Nauk.*, **2012**, 10, 29-37.
8. Yue, J.; Wei, W.; Lam, C.M.; Zhao, Y.J.; Dong, M.; Zhang, L.R.; Zhang, L.H.; Lee, H.C. CD38/cADPR/Ca²⁺ pathway promotes cell proliferation and delays nerve growth factor-induced differentiation in PC12 cells. *J. Biol. Chem.*, **2009**, 284, 29335-29342.
9. Graeff, R.; Liu, Q.; Kriksunov, I.A.; Kotaka, M.; Oppenheimer, N.; Hao, Q.; Lee, H.C. Mechanism of cyclizing NAD to cyclic ADP-ribose by ADP-ribosyl cyclase and CD38. *J. Biol. Chem.*, **2009**, 284, 27629-27636.
10. Howard, M.; Grimaldi, J. C.; Bazan, J. F.; Lund, F. E.; Santos-Argumedo, L.; Parkhouse, R. M.; Walseth, T. F.; Lee, H. C. Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. *Science*, **1993**, 262, 1056-1059.
11. Kim, H.; Jacobson, E.L.; Jacobson, M. K. Synthesis and degradation of cyclic ADP-ribose by NAD-glycohydrolases. *Science*, **1993**, 261, 1330-1333.
12. Lee, H. C.; Zocchi, E.; Guida, L.; Franco, L.; Benatti, U.; De Flora, A. Production and hydrolysis of cyclic ADP-ribose at the outer surface of human erythrocytes. *Biochem. Biophys. Res. Commun.*, **1993**, 191, 639-645.
13. Takasawa, S.; Tohgo, A.; Noguchi, N.; Koguma, T.; Nata, K.; Sugimoto, T.; Yonekura, H.; Okamoto, H. Synthesis and hydrolysis of cyclic ADP-ribose by human leukocyte antigen CD38 and inhibition of the hydrolysis by ATP. *J. Biol. Chem.*, **1993**, 268, 26052-26054.
14. Bezin, S.; Charpentier, G.; Lee, H.C.; Baux, G.; Fossier, P.; Cancela, J. M. Regulation of nuclear Ca²⁺ signaling by translocation of the Ca²⁺ messenger synthesizing enzyme ADP-ribosyl cyclase during neuronal depolarization. *J. Biol. Chem.*, **2008**, 283, 27859-27870.

15. Akimoto, N.; Kamiyama, Y.; Yamafuji, M.; Fujita, K.; Seike, T.; Kido, M.A.; Yokoyama, S.; Higashida, H.; Noda, M. Immunohistochemistry of CD38 in different cell types in the hypothalamus and pituitary of male mice. *Messenger*, **2013**, *1*, 54-61.
16. Ceni, C.; Pochon, N.; Villaz, M.; Muller-Steffner, H.; Schubert, F.; Baratier, J.; De Waard, M.; Ronjat, M.; Moutin, M.J. The CD38-independent ADP-ribosyl cyclase from mouse brain synaptosomes: a comparative study of neonate and adult brain. *Biochem. J.*, **2006**, *395*, 417–426.
17. Malavasi, F.; Deaglio, S.; Funaro, A.; Ferrero, E.; Horenstein, A.L.; Ortolan, E.; Vaisitti, T.; Aydin, S. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. *Physiol. Rev.*, **2008**, *88*, 841–886.
18. Cakir-Kiefer, C.; Muller-Steffner, H.; Oppenheimer, N.; Schubert, F. Kinetic competence of the cADP-ribose-CD38 complex as an intermediate in the CD38/NAD⁺ glycohydrolase-catalysed reactions: implication for CD38 signaling. *Biochem. J.*, **2001**, *358*, 399–406.
19. Zhao, Y.J.; Lam, C.M.; Lee, H.C. The membrane-bound enzyme CD38 exists in two opposing orientations. *Sci. Signal.*, **2012**, *5*(241), ra67.
20. Sun, L.A.; Adebajo, O.A.; Koval, A.; Anandatheerthavarada, H.K.; Iqbal, J.; Wu, X.Y.; Moonga, B.S.; Wu, X.B.; Biswas, G.; Bevis, P.J.; Kumegawa, M.; Epstein, S.; Huang, C.L.; Avadhani, N.G.; Abe, E.; Zaidi, M. Novel mechanism for coupling cellular intermediary metabolism to cytosolic Ca²⁺ signaling via CD38/ADP-ribosyl cyclase a putative intracellular NAD⁺ sensor. *FASEB J.*, **2002**, *16*, 302–314.
21. Yamada, M.; Mizuguchi, M.; Otsuka, N.; Ikeda, K.; Takahashi, H. Ultrastructural localization of CD38 immunoreactivity in rat brain. *Brain Res.*, **1997**, *756*(1-2), 52-60.
22. Salmina, A.B.; Okuneva, O.S.; Malinovskaya, N.A.; Taranushenko, T.E.; Morgun, A.V.; Mantorova, N.S.; Mikhutkina, S.V. NAD⁺-dependent mechanisms of disturbances of viability of brain cells during the acute period of hypoxic-ischemic perinatal injury. *J. Neurochem.*, **2008**, *2*, 215–221.
23. Higashida, H.; Zhang, J.S.; Mochida, S.; Chen, X.L.; Shin, Y.; Noda, M.; Hossain, K.Z.; Hoshi, N.; Hashii, M.; Shigemoto, R.; Nakanishi, S.; Fukuda, Y.; Yokoyama, S. Subtype-specific coupling with ADP-ribosyl cyclase of metabotropic glutamate receptors in retina, cervical superior ganglion and NG108-15 cells. *J. Neurochem.*, **2003**, *85*, 1148–1158.
24. Noda, M.; Yasuda, S.; Okada, M.; Higashida, H.; Shimada, A.; Iwata, N.; Ozaki, N.; Nishikawa, K.; Shirasawa, S.; Uchida, M.; Aoki, S.; Wada, K. Recombinant human 5-HT_{5A} receptors stably expressed in C6 glioma cells couple to multiple signal transduction pathways. *J. Neurochem.*, **2003**, *84*, 222–232.
25. Wilson, H.L.; Dipp, M.; Thomas, J.T.; Lad, C.; Galione, A.; Evans, A.M. ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase act as redox sensors. *J. Biol. Chem.*, **2001**, *276*, 1180–1188.
26. Ceni, C.; Muller-Steffner, H.; Lund, F.; Pochon, N.; Schweitzer, A.; De Waard, M.; Schubert, F.; Villaz, M.; Moutin, M.J. Evidence for an intracellular ADP-ribosyl cyclase/NAD⁺-glycohydrolase in brain from CD38-deficient mice. *J. Biol. Chem.*, **2003**, *278*, 40670–40678.
27. Aksoy, P.; White, T.; Thompson, M. Regulation of intracellular levels of NAD⁺: a novel role for CD38. *Biochem. Biophys. Res. Commun.*, **2006**, *10*, 1016.

28. Chini, E.N. CD38 as a regulator of cellular NAD⁺: a novel potential pharmacological target for metabolic conditions. *Curr. Pharm. Des.*, **2009**, *15*, 57–63.
29. Tang B.L.; Chua C.E.L. SIRT1 and neuronal diseases. *Mol. Aspects Med.* **2008**, *29*, 187–200.
30. Cohem D.E.; Supinski A.M.; Bonkowski M.S.; Donmez G.; Guarente L.P. Neuronal SIRT1 regulates endocrine and behavioral responses to calorie restriction. *Genes Devel.*, **2009**, *23*, 2812–2817.
31. Michan, S.; Li, Y.; Chou, M.M-H.; Parrella, E.; Ge, H.; Long, J.M.; Allard, J.S.; Lewis, K.; Miller, M.; Xu, W.; Mervis, R.F.; Chen, J.; Guerin, K.I.; Smith, L.E.; McBurney, M.W.; Sinclair, D.A.; Baudry, M.; de Cabo, R.; Longo, V.D. SIRT1 is essential for normal cognitive function and synaptic plasticity. *J. Neurosci.*, **2010**, *30*, 9695–9707.
32. Aksoy, P.; Escande, C.; White, T.A.; Thompson, M.; Soares, S.; Benech, J.C.; Chini, E.N. Regulation of SIRT 1 mediated NAD dependent deacetylation: a novel role for the multifunctional enzyme CD38. *Biochem. Biophys. Res. Commun.*, **2006**, *349*, 353–359.
33. Sahar, S.; Nin, V.; Barbosa, M.T.; Chini, E.N.; Sassone-Corsi, P. Altered behavioral and metabolic circadian rhythms in mice with disrupted NAD⁺ oscillation. *Aging*, **2011**, *3*, 1–9.
34. Houtkooper, R.H.; Canto, C.; Wanders, R.J.; Auwerx, J. The secret life of NAD⁺: an old metabolite controlling new metabolic signaling pathways. *Endocrine Reviews*, **2010**, *31*, 194–223.
35. Hashii, M.; Shuto, S.; Fukuoka, M.; Kudoh, T.; Matsuda, A.; Higashida, H. Amplification of depolarization-induced and ryanodine- sensitive cytosolic Ca²⁺ elevation by synthetic carbocyclic analogs of cyclic ADP-ribose and their antagonistic effects in NG108-15 neuronal cells. *J. Neurochem.*, **2005**, *94*, 316–323.
36. Morikawa, H.; Khodakhah, K.; Williams, J.T. Two intracellular pathways mediate metabotropic glutamate receptor-induced Ca²⁺ mobilization in dopamine neurons. *J. Neurosci.*, **2003**, *23*, xxx-157.
37. Chung, K.K.; Freestone, P.S.; Lipski, J. Expression and functional properties of TRPM2 channels in dopaminergic neurons of the substantianigra of the rat. *J. Neurophysiol.*, **2011**, *106*, 2865–2875.
38. Toth, B.; Csanady L. Identification of direct and indirect effectors of the transient receptor potential melastatin 2 (TRPM2) cation channel. *J. Biol. Chem.*, **2010**, *285*, 30091–30102.
39. Massullo, P.; Sumoza-Toledo, A.; Bhagat, H.; Partida-Sanchez, S. TRPM channels, calcium and redox sensors during innate immune responses. *Seminars Cell Devel. Biol.*, **2006**, *17*, 654–666.
40. Higashida, H.; Lopatina, O.; Yoshihara, T.; Pichugina, Y.A.; Soumarokov, A.A.; Munesue, T.; Minabe, Y.; Kikuchi, M.; Ono, Y.; Korshunova, N.; Salmina, A.B. Oxytocin signal and social behaviour: comparison among adult and infant oxytocin, oxytocin receptor and CD38 gene knockout mice. *J. Neuroendocrinol.*, **2010**, *22*, 373–379.
41. Lu, H.; Burns, D.; Garnier, P.; Wei, G.; Zhu, K.; Ying, W. P2X7 receptors mediate NADH transport across the plasma membrane of astrocytes. *Biochem. Biophys. Res. Comm.*, **2007**, *362*, 946–950.
42. Bruzzone, S.; Basile, G.; Chothi, M.P.; Nobbio, L.; Usai, C.; Jacchetti, E.; Schenone, A.; Guse A.H; Di Virgilio, F.; De Flora, A.; Zocchi, E. Diadenosinehomodinucleotide products of ADP-ribosyl cyclases behave as modulators of the purinergic receptor P2X7. *J. Biol. Chem.*, **2010**, *285*, 21165–21174.

43. Malavasi, F.; Deaglio, S.; Zaccarello, G.; Horenstein, A.L.; Chillemi, A.; Audrito, V.; Serra, S.; Gandione, M.; Zitella, A.; Tizzani, A. The hidden life of NAD⁺-consuming ectoenzymes in the endocrine system. *J. Mol. Endocrinol.*, **2010**, *45*, 183–191.
44. Xu, X.J.; Boumechache, M.; Robinson, L.E.; Marschall, V.; Gorecki, D.C.; Masin, M.; Murrell-Lagnado, R.D. Splice variants of the P2X7 receptor reveal differential agonist dependence and functional coupling with pannexin-1. *J Cell Sci.*, **2012**, *125*, 3776-3789.
45. Sandilos, J.K.; Bayliss, D.A. Physiological mechanisms for the modulation of pannexin 1 channel activity. *J Physiol.*, **2012**, *590*, 6257-6266.
46. Bennett, M.V.; Garré, J.M.; Orellana, J.A.; Bukauskas, F.F.; Nedergaard, M.; Sáez, J.C. Connexin and pannexin hemichannels in inflammatory responses of glia and neurons. *Brain Res.*, **2012**, *1487*, 3-15.
47. Naviaux, R.K.; Zolkipli, Z.; Wang, L.; Nakayama, T.; Naviaux, J.C.; Le, T.P.; Schuchbauer, M.A.; Rogac, M.; Tang, Q.; Dugan, L.L.; Powell, S.B. Antipurinergic Therapy Corrects the Autism-Like Features in the Poly(IC) Mouse Model. *PLoS One*, **2013**, *8*, e57380.
48. Heinrichs, M.; Domes, G. Neuropeptides and social behaviour: effects of oxytocin and vasopressin in humans. *Prog. Brain. Res.*, **2008**, *170*, 337-350.
49. Ebstein, R.P.; Israel, S.; Lerer, E.; Uzefovsky, F.; Shalev, I.; Gritsenko, I.; Riebold, M.; Salomon, S.; Yirmiya, N. Arginine vasopressin and oxytocin modulate human social behavior. *Ann. N. Y. Acad. Sci.*, **2009**, *1167*, 87-102.
50. Veenema, A.H.; Neumann, I.D. Central vasopressin and oxytocin release: regulation of complex social behaviours. *Prog. Brain Res.*, **2008**, *170*, 261-276.
51. Viero, C.; Shibuya, I.; Kitamura, N.; Verkhatsky, A.; Fujihara, H.; Katoh, A.; Ueta, Y.; Zingg H.H.; Chvatal, A.; Sykova, E.; Dayanithi, G. Oxytocin: Crossing the bridge between basic science and pharmacotherapy. *CNS Neurosci. Ther.*, **2010**, *16*, e138-56.
52. Bosch, O.J.; Meddle, S.L.; Beiderbeck, D.I.; Douglas, A.J.; Neumann, I.D. Brain oxytocin correlates with maternal aggression: link to anxiety. *J. Neurosci.*, **2005**, *25*, 6807-6815.
53. Herzmann, G.; Young, B.; Bird, C.W.; Curran, T. Oxytocin can impair memory for social and non-social visual objects: a within-subject investigation of oxytocin's effects on human memory. *Brain Res.*, **2012**, *1451*, 65-73.
54. Neumann, I.D. Brain oxytocin: a key regulator of emotional and social behaviours in both females and males. *J. Neuroendocrinol.*, **2008**, *20*, 858-65.
55. Marazziti, D.; Roncaglia, I.; Del Debbio, A.; Bianchi, C.; Massimetti, G.; Origlia, N.; Domenici, L.; Piccinni, A.; Dell'Osso, L. Brain-derived neurotrophic factor in romantic attachment. *Psychol. Med.*, **2009**, *39*, 1927-1930.
56. Strathearn, L.; Fonagy, P.; Amico, J.; Montague, P.R. Adult attachment predicts maternal brain and oxytocin response to infant cues. *Neuropsychopharmacology*, **2009**, *34*, 2655-2666.
57. Kret, M.E.; De Dreu, C.K. Oxytocin-motivated ally selection is moderated by fetal testosterone exposure and empathic concern. *Front. Neurosci.*, **2013**, *7*, 1.
58. Dai, L.; Carter, C.S.; Ying, J.; Bellugi, U.; Pournajafi-Nazarloo, H.; Korenberg, J.R. Oxytocin and vasopressin are dysregulated in Williams Syndrome, a genetic disorder affecting social behavior. *PLoS One.*, **2012**, *7*(6), e38513.

59. Lucas, M.; Frenois, F.; Cador, M.; Le Moine, C. Remodeling of the neuronal circuits underlying opiate-withdrawal memories following remote retrieval. *Neurobiol. Learn. Mem.*, **2012**, *97*, 47-53.
60. Scheele, D.; Striepens, N.; Güntürkün, O.; Deutschländer, S.; Maier, W.; Kendrick, K.M.; Hurlemann, R. Oxytocin modulates social distance between males and females. *J. Neurosci.* **2012**, *32*, 16074-16079.
61. Neumann, I.D.; Landgraf, R. Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors. *Trends Neurosci.*, **2012**, *35*(11), 649-659.
62. Atzil, S.; Hendler, T.; Zagoory-Sharon, O.; Winetraub, Y.; Feldman, R. Synchrony and specificity in the maternal and the paternal brain: relations to oxytocin and vasopressin. *J. Am. Acad. Child. Adolesc. Psychiatry.*, **2012**, *51*, 798-811.
63. Zheng, J.; Babygirija, R.; Bülbül, M.; Cerjak, D.; Ludwig, K.; Takahashi, T. Hypothalamic oxytocin mediates adaptation mechanism against chronic stress in rats. *Am. J. Physiol. Gastrointest. Liver Physiol.*, **2010**, *299*, G946-G953.
64. Pournajafi-Nazarloo, H.; Kenkel, W.; Mohsenpour, S.R.; Sanzenbacher, L.; Saadat, H.; Partoo, L.; Yee, J.; Azizi, F.; Carter, C.S. Exposure to chronic isolation modulates receptors mRNAs for oxytocin and vasopressin in the hypothalamus and heart. *Peptides*, **2013**, *43C*, 20-26.
65. Windle, R.J.; Gamble, L.E.; Kershaw, Y.M.; Wood, S.A.; Lightman, S.L.; Ingram, C.D. Gonadal steroid modulation of stress-induced hypothalamo-pituitary-adrenal activity and anxiety behavior: role of central oxytocin. *Endocrinology*, **2006**, *147*, 2423-2431.
66. Miller, M.; Bales, K.L.; Taylor, S.L.; Yoon, J.; Hostetler, C.M.; Carter, C.S.; Solomon, M. Oxytocin and vasopressin in children and adolescents with autism spectrum disorders: sex differences and associations with symptoms. *Autism Res.*, 2013. Feb 14. [Epub ahead of print] doi: 10.1002/aur.1270.
67. Shughrue, P.J.; Dellovade, T.L.; Merchenthaler, I. Estrogen modulates oxytocin gene expression in regions of the rat supraoptic and paraventricular nuclei that contain estrogen receptor-beta. *Prog. Brain Res.*, **2002**, *139*, 15-29.
68. Dayanithi, G.; Viero, C.; Shibuya, I. The role of calcium in the action and release of vasopressin and oxytocin from CNS neurones/terminals to the heart. *J. Physiol. Pharmacol.*, **2008**, *59*, 7-26.
69. Knott, T.K.; Hussy, N.; Cuadra, A.E.; Lee, R.H.; Ortiz-Miranda, S.; Custer, E.E.; Lemos, J.R. Adenosine triphosphate appears to act via different receptors in terminals versus somata of the hypothalamic neurohypophysial system. *J. Neuroendocrinol.*, **2012**, *24*, 681-689.
70. Widmer, H.; Ludwig, M.; Bancel, F.; Leng, G.; Dayanithi, G. Neurosteroid regulation of oxytocin and vasopressin release from the rat supraoptic nucleus. *J. Physiol.*, **2003**, *548*, 233-44.
71. De Crescenzo, V.; ZhuGe, R.; Velázquez-Marrero, C.; Lifshitz, L.M.; Custer, E.; Carmichael, J.; Lai, F.A.; Tuft, R.A.; Fogarty, K.E.; Lemos, J.R.; Walsh, J.V. Jr. Ca^{2+} syntillas, miniature Ca^{2+} release events in terminals of hypothalamic neurons, are increased in frequency by depolarization in the absence of Ca^{2+} influx. *J. Neurosci.*, **2004**, *24*, 1226-1235.
72. Leng, G.; Meddle, S.L.; Douglas, A.J. Oxytocin and the maternal brain. *Curr. Opin. Pharmacol.*, **2008**, *8*, 731-734.

73. Dayanithi, G.; Forostyak, O.; Ueta, Y.; Verkhatsky, A.; Toescu, E.C. Segregation of calcium signalling mechanisms in magnocellular neurones and terminals. *Cell Calcium*, **2012**, *51*, 293-299.
74. Tobin, V.; Leng, G.; Ludwig, M. The involvement of actin, calcium channels and exocytosis proteins in somato-dendritic oxytocin and vasopressin release. *Front. Physiol.*, **2012**, *3*, 261.
75. Tobin, V.A.; Ludwig, M. The actin filament and dendritic peptide release. *Biochem. Soc. Trans.*, **2007**, *35*, 1243-1246.
76. Lemos, J.R.; Ortiz-Miranda, S.I.; Cuadra, A.E.; Velázquez-Marrero, C.; Custer, E.E.; Dad, T.; Dayanithi, G. Modulation/physiology of calcium channel sub-types in neurosecretory terminals. *Cell Calcium*, **2012**, *51*, 284-292.
77. Modahl, C.; Green, L.; Fein, D.; Morris, M.; Waterhouse, L.; Feinstein, C.; Levin, H. Plasma oxytocin levels in autistic children. *Biol. Psychiatry*, **1998**, *43*, 270-277.
78. Hollander, E.; Novotny, S.; Hanratty, M.; Yaffe, R.; DeCaria, C.M.; Aronowitz, B.R.; Mosovich, S. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. *Neuropsychopharmacology*, **2003**, *28*, 193-198.
79. Guastella, A.J.; Howard, A.L.; Dadds, M.R.; Mitchell, P.; Carson, D.S. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. *Psychoneuroendocrinology*, **2009**, *34*, 917-23.
80. Hollander, E.; Bartz, J.; Chaplin, W.; Phillips, A.; Sumner, J.; Soorya, L.; Anagnostou, E.; Wasserman, S. Oxytocin increases retention of social cognition in autism. *Biol. Psychiatry*, **2007**, *61*, 498-503.
81. Gurrieri, F.; Neri, G. Defective oxytocin function: a clue to understanding the cause of autism? *BMC Med.*, **2009**, *7*, 63.
82. Israel, S.; Lerer, E.; Shalev, I.; Uzefovsky, F.; Reibold, M.; Bachner-Melman, R.; Granot, R.; Bornstein, G.; Knafo, A.; Yirmiya, N.; Ebstein, R.P. Molecular genetic studies of the arginine vasopressin 1a receptor (AVPR1a) and the oxytocin receptor (OXTR) in human behaviour: from autism to altruism with some notes in between. *Prog. Brain Res.*, **2008**, *170*, 435-449.
83. Gregory, S.G.; Connelly, J.J.; Towers, A.J.; Johnson, J.; Biscocho, D.; Markunas, C.A.; Lintas, C.; Abramson, R.K.; Wright, H.H.; Ellis, P.; Langford, C.F.; Worley, G.; Delong, G.R.; Murphy, S.K.; Cuccaro, M.L.; Persico, A.; Pericak-Vance, M.A. Genomic and epigenetic evidence for oxytocin receptor deficiency in autism. *BMC Med.*, **2009**, *7*, 62.
84. Munesue, T.; Yokoyama, S.; Nakamura, K.; Anitha, A.; Yamada, K.; Hayashi, K.; Asaka, T.; Liu, H.X.; Jin, D.; Koizumi, K.; Islam, M.S.; Huang, J.J.; Ma, W.J.; Kim, U.H.; Kim, S.J.; Park, K.; Kim, D.; Kikuchi, M.; Ono, Y.; Nakatani, H.; Suda, S.; Miyachi, T.; Hirai, H.; Salmina, A.; Pichugina, Y.A.; Soumarokov, A.A.; Takei, N.; Mori, N.; Tsujii, M.; Sugiyama, T.; Yagi, K.; Yamagishi, M.; Sasaki, T.; Yamasue, H.; Kato, N.; Hashimoto, R.; Taniike, M.; Hayashi, Y.; Hamada, J.; Suzuki, S.; Ooi, A.; Noda, M.; Kamiyama, Y.; Kido, M.A.; Lopatina, O.; Hashii, M.; Amina, S.; Malavasi, F.; Huang, E.J.; Zhang, J.; Shimizu, N.; Yoshikawa, T.; Matsushima, A.; Minabe, Y.; Higashida, H. Two genetic variants of CD38 in subjects with autism spectrum disorder and controls. *Neurosci. Res.*, **2010**, *67*, 181-191.

85. Jin, D.; Liu, H.X.; Hirai, H.; Torashima, T.; Nagai, T.; Lopatina, O.; Shnayder, N.A.; Yamada, K.; Noda, M.; Seike, T.; Fujita, K.; Takasawa, S.; Yokoyama, S.; Koizumi, K.; Shiraishi, Y.; Tanaka, S.; Hashii, M.; Yoshihara, T.; Higashida, K.; Islam, M.S.; Yamada, N.; Hayashi, K.; Noguchi, N.; Kato, I.; Okamoto, H.; Matsushima, A.; Salmina, A.; Munesue, T.; Shimizu, N.; Mochida, S.; Asano, M.; Higashida, H. CD38 is critical for social behaviour by regulating oxytocin secretion. *Nature*, **2007**, *446*, 41-45.
86. Liu, H.X.; Lopatina, O.; Higashida, C.; Tsuji, T.; Kato, I.; Takasawa, S.; Okamoto, H.; Yokoyama, S.; Higashida, H. Locomotor activity, ultrasonic vocalization and oxytocin levels in infant CD38 knockout mice. *Neurosci. Lett.*, **2008**, *448*, 67-70.
87. Lopatina, O.; Liu, H.X.; Amina, S.; Hashii, M.; Higashida, H. Oxytocin-induced elevation of ADP-ribosylcyclase activity, cyclic ADP-ribose or Ca^{2+} concentrations is involved in autoregulation of oxytocin secretion in the hypothalamus and posterior pituitary in male mice. *Neuropharmacology*, **2010**, *58*, 50-55.
88. Higashida, H.; Yokoyama, S.; Munesue, T.; Kikuchi, M.; Minabe, Y.; Lopatina, O. CD38 gene knockout juvenile mice: a model of oxytocin signal defects in autism. *Biol. Pharm. Bull.*, **2011**, *34*, 1369-1372.
89. Mangas, A.; Bodet, D.; Duleu, S.; Yajeya, J.; Geffard, M.; Coveñas, R. Direct visualization of retinoic acid in the rat hypothalamus: an immunohistochemical study. *Neurosci. Lett.*, **2012**, *509*, 64-68.
90. Stoney, P.; Morgan, P.; McCaffery, P. Retinoic acid regulates growth-related gene expression in the rat hypothalamus. *Endocrine Abstracts*, **2012**, *29*, 1111.
91. Kato, I.; Yamamoto, Y.; Fujimura, M.; Noguchi, N.; Takasawa, S.; Okamoto, H. CD38 disruption impairs glucose-induced increases in cyclic ADP-ribose, $[Ca^{2+}]_i$, and insulin secretion. *J. Biol. Chem.*, **1999**, *274*, 1869-1872.
92. Higashida, H.; Yokoyama, S.; Huang, J.J.; Liu, L.; Ma, W.J.; Akther, S.; Higashida, C.; Kikuchi, M.; Minabe, Y.; Munesue, T. Social memory, amnesia, and autism: brain oxytocin secretion is regulated by NAD^+ metabolites and single nucleotide polymorphisms of CD38. *Neurochem. Int.*, **2012**, *61*, 828-838.
93. Lopatina, O.; Inzhutova, A.; Salmina, A.B.; Higashida, H. The roles of oxytocin and CD38 in social or parental behaviors. *Front. Neurosci.*, **2012**, *6*, 182.
94. Liu, H.X.; Lopatina, O.; Higashida, C.; Fujimoto, H.; Akther, S.; Inzhutova, A.; Liang, M.; Zhong, J.; Tsuji, T.; Yoshihara, T.; Sumi, K.; Ishiyama, M.; Ma, W.J.; Ozaki, M.; Yagitani, S.; Yokoyama, S.; Mukaida, N.; Sakurai, T.; Hori, O.; Yoshioka, K.; Hirao, A.; Kato, Y.; Ishihara, K.; Kato, I.; Okamoto, H.; Cherepanov, S.M.; Salmina, A.B.; Hirai, H.; Asano, M.; Brown, D.A.; Nagano, I.; Higashida, H. Displays of paternal mouse pup retrieval following communicative interaction with maternal mates. *Nat. Commun.*, **2013**, *4*, 1346.
95. Feldman, R.; Zagoory-Sharon, O.; Weisman, O.; Schneiderman, I.; Gordon, I.; Maoz, R.; Shalev, I.; Ebstein, R.P. Sensitive parenting is associated with plasma oxytocin and polymorphisms in the OXTR and CD38 genes. *Biol. Psychiatry*, **2012**, *72*, 175-181.
96. Andari, E.; Duhamel, J.R.; Zalla, T.; Herbrecht, E.; Leboyer, M.; Sirigu, A. Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. *Proc. Natl. Acad. Sci. U.S.A.*, **2010**, *107*, 4389-4394.
97. Huffmeijer, R.; Alink, L.R.; Tops, M.; Grewen, K.M.; Light, K.C.; Bakermans-Kranenburg, M.J.; Ijzendoorn, M.H. Salivary levels of oxytocin remain elevated for more than two hours after intranasal oxytocin administration. *NeuroEndocrinol. Lett.*, **2012**, *33*, 21-25.

98. Takase, K.; Oda, S.; Kuroda, M.; Funato, H. Monoaminergic and neuropeptidergic neurons have distinct expression profiles of histone deacetylases. *PLoS One*, **2013**, 8, e58473.
99. Bethlehem, R.A.; van Honk, J.; Auyeung, B.; Baron-Cohen S. Oxytocin, brain physiology, and functional connectivity: A review of intranasal oxytocin fMRI studies. *Psychoneuroendocrinology*, 2012, xxxxx
100. Yamasue, H. Function and structure in social brain regions can link oxytocin-receptor genes with autistic social behavior. *Brain Dev.*, **2013**, 35, 111-118.
101. Liberzon, I.; Chalmers, D.T.; Mansour, A.; Lopez, J.F.; Watson, S.J.; Young, E.A. Glucocorticoid regulation of hippocampal oxytocin receptor binding. *Brain Res.*, **1994**, 650, 317–322.
102. Cohen, H.; Kaplan, Z.; Kozlovsky, N.; Gidron, Y.; Matar, M.A.; Zohar, J. Hippocampal microinfusion of oxytocin attenuates the behavioural response to stress by means of dynamic interplay with the glucocorticoid-catecholamine responses. *J. Neuroendocrinol.*, **2010**, 22(8), 889-904.
103. Neumann, I.D.; Wigger, A.; Liebsch, G.; Holsboer, F.; Landgraf, R. Increased basal activity of the hypothalamo-pituitary-adrenal axis during pregnancy in rats bred for high anxiety-related behaviour. *Psychoneuroendocrinology*, **1998**, 23, 449-463.
104. Ferguson, J.N.; Aldag, J.M.; Insel, T.R.; Young, L.J. Oxytocin in the medial amygdale is essential for social recognition in the mouse. *J. Neurosci.*, **2001**, 21, 8278–8285.
105. Hurlemann, R.; Patin, A.; Onur, O. A.; Cohen, M.X.; Baumgartner, T.; Metzler, S.; Dziobek, I.; Gallinat, J.; Wagner, M.; Maier, W.; Kendrick, K.M. Oxytocin enhances amygdala-dependent, socially reinforced learning and emotional empathy in humans. *J. Neurosci.*, **2010**, 30, 4999–5007.
106. Landgraf, R.; Neumann, I.D. Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. *Front. Neuroendocrinol.*, **2004**, 25, 150–176.
107. Neumann, I.D. Stimuli and consequences of dendritic release of oxytocin within the brain. *Biochem. Soc. Trans.*, **2007**, 35, 1252-1257.
108. Knobloch, H.S.; Charlet, A.; Hoffmann, L.C.; Eliava, M.; Khrulev, S.; Cetin, A.H.; Osten, P.; Schwarz, M.K.; Seeburg, P.H.; Stoop, R.; Grinevich, V. Evoked axonal oxytocin release in the central amygdala attenuates fear response. *Neuron*, **2012**, 73, 553-566.
109. Higashida, H.; Munesue, T.; Yokoyama, S.; Hashii, M.; Koizumi, K.; Matsushima, A. A missense mutation in CD38 associated with autism spectrum disorder in three pedigrees. In: *Autism - A Neurodevelopmental Journey from Genes to Behaviour*; Dr. Valsamma Eapen, Ed.; In Tech: **2011**; pp.183-196.
110. GeneCards database. Transient receptor potential cation channel, subfamily M, member 2. <http://www.genecards.org/cgi-bin/carddisp.pl?gene=TRPM2> (Accessed April 7, **2013**).
111. Huber, D.; Veinante, P.; Stoop, R.; Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. *Science*, **2005**, 308, 245-248.
112. Blouin, A.M.; Fried, I.; Wilson, C.L.; Staba, R.J.; Behnke, E.J.; Lam, H.A.; Maidment, N.T.; Karlsson, K.Æ.; Lapierre, J.L.; Siegel, J.M. Human hypocretin and melanin-concentrating hormone levels are linked to emotion and social interaction. *Nat. Commun.*, **2013**, 4, 1547.

113. Andari, E.; Schneider, F.C.; Mottollese, R.; Vindras, P.; Sirigu, A. Oxytocin's fingerprint in personality traits and regional brain volume. *Cereb. Cortex.*, **2012**, xxxxxxxx
114. Petrovic, P.; Kalisch, R.; Singer, T.; Dolan, R.J. Oxytocin attenuates affective evaluations of conditioned faces and amygdala activity. *J. Neurosci.*, **2008**, 28, 6607-6615.
115. Wang, Y.; He, Z.; Zhao, C.; Li, L. Medial amygdala lesions modify aggressive behavior and immediate early gene expression in oxytocin and vasopressin neurons during intermale exposure. *Behav. Brain Res.*, **2013**, 245, 42-49.
116. Choleris, E.; Little, S.R.; Mong, J.A.; Puram, S.V.; Langer, R.; Pfaff, D.W. Microparticle-based delivery of oxytocin receptor antisense DNA in the medial amygdala blocks social recognition in female mice. *Proc. Natl. Acad. Sci. U S A.*, **2007**, 104, 4670-4675.
117. Rosenfeld, A.J.; Lieberman, J.A.; Jarskog, L.F. Oxytocin, dopamine, and the amygdala: a neurofunctional model of social cognitive deficits in schizophrenia. *Schizophr. Bull.*, **2011**, 37, 1077-1087.
118. Domes, G.; Heinrichs, M.; Michel, A.; Berger, C.; Herpertz, S.C. Oxytocin improves “mind- reading” in humans. *Biol. Psychiat.*, **2007**, 61, 731-733.
119. Gamer, M. Does the amygdala mediate oxytocin effects on socially reinforced learning? *J. Neurosci.*, **2010**, 30, 9347-9348.
120. Ebner, K.; Bosch, O.J.; Krömer, S.A.; Singewald, N.; Neumann, I.D. Release of oxytocin in the rat central amygdala modulates stress-coping behavior and the release of excitatory amino acids. *Neuropsychopharmacology*, **2005**, 30, 223-230.
121. Furman, D.J.; Chen, M.C.; Gotlib, I.H. Variant in oxytocin receptor gene is associated with amygdala volume. *Psychoneuroendocrinology*, **2011**, 36, 891-897.
122. Arakawa, H.; Arakawa, K.; Deak, T. Oxytocin and vasopressin in the medial amygdala differentially modulate approach and avoidance behavior toward illness-related social odor. *Neuroscience*, **2010**, 171, 1141-1151.
123. Crawley, J.N. Translational animal models of autism and neurodevelopmental disorders. *Dialogues Clin. Neurosci.*, **2012**, 14, 293-305.
124. Stavropoulos, K.K.; Carver, L.J. Research review: Social motivation and oxytocin in autism - implications for joint attention development and intervention. *J. Child Psychol. Psychiatry.*, **2013**, xxxxx
125. Bale, T.L.; Baram, T.Z.; Brown, A.S.; Goldstein, J.M.; Insel, T.R.; McCarthy, M.M.; Nemeroff, C.B.; Reyes, T.M.; Simerly, R.B.; Susser, E.S.; Nestler, E.J. Early life programming and neurodevelopmental disorders. *Biol. Psychiat.*, **2010**, 68,314-319.
126. Zocchi, L.; Sassone-Corsi, P. SIRT1-mediated deacetylation of MeCP2 contributes to BDNF expression. *Epigenetics*, **2012**, 7, 695-700.
127. Ullah, N.; Lee, H.Y.; Naseer, M.I.; Ullah, I.; Suh, J.W.; Kim, M.O. Nicotinamide inhibits alkylating agent-induced apoptotic neurodegeneration in the developing rat brain. *PLoS One*, **2011**, 6(12), e27093.
128. Ceni, C.; Pochon, N.; Brun, V.; Muller- Steffner, H.; Andrieux, A.; Grunwald, D.; Schubert, F.; De Waard, M.; Lund, F.; Villaz, M.; Moutin, M.J.CD38-dependent ADP-ribosyl cyclase in developing and adult mouse brain. *Biochem. J.*, **2003**, 370, 175-183.

129. Salmina, A.B. Neuron-glia interactions as therapeutic targets in neurodegeneration. *J. Alzheimers Dis.*, **2009**, *16*, 485-502.
130. Carter, C.S.; Boone, E.M.; Pournajafi-Nazarloo, H.; Bales, K.L. Consequences of early experiences and exposure to oxytocin and vasopressin are sexually dimorphic. *Dev. Neurosci.*, **2009**, *31*, 332-341.
131. Rankin, S.L.; Partlow, G.D; McCurdy, R.D.; Giles, E.D; Fisher, K.R. Postnatal neurogenesis in the vasopressin and oxytocin-containing nucleus of the pig hypothalamus. *Brain Res.*, **2003**, *97*, 189-196.
132. Raymond, A.D.; Kucherepa, N.N.; Fisher, K.R.; Halina, W.G.; Partlow, G.D. Neurogenesis of oxytocin-containing neurons in the paraventricular nucleus (PVN) of the female pig in 3 reproductive states: puberty gilts, adult gilts and lactating sows. *Brain Res.*, **2006**, *1102*, 44-51.
133. Bertsch, K.; Schmidinger, I.; Neumann, I.D; Herpertz, S.C. Reduced plasma oxytocin levels in female patients with borderline personality disorder. *Horm. Behav.*, **2013**, *63*, 424-429.
134. Lieberwirth, C.; Wang, Z. The social environment and neurogenesis in the adult Mammalian brain. *Front. Hum. Neurosci.*, **2012**, *6*, 118.
135. Lévy, F.; Gheusi, G.; Keller, M. Plasticity of the parental brain: a case for neurogenesis. *J. Neuroendocrinol.*, **2011**, *23*, 984-993.
136. Mak, G.K.; Weiss, S. Paternal recognition of adult offspring mediated by newly generated CNS neurons. *Nat. Neurosci.*, **2010**, *13*, 753-758.
137. Feierstein, C.E.; Lazarini, F.; Wagner, S.; Gabellec, M.M.; de Chaumont, F.; Olivo-Marin, J.C.; Boussin, F.D.; Lledo, P.M.; Gheusi, G. Disruption of adult neurogenesis in the olfactory bulb affects social interaction but not maternal behavior. *Front. Behav. Neurosci.*, **2010**, *4*, 176.
138. Feierstein, C.E. Linking adult olfactory neurogenesis to social behavior. *Front. Neurosci.*, **2012**, *6*, 173.
139. Musaelyan, K.; Anacker, C.; Zunszain, P. A.; Pariante, C. M. The effects of oxytocin on hippocampal neurogenesis. In: *Neural Development & Plasticity Abstracts*, Proceedings of The Physiological Society, Poster Communications, King's College London, UK, **2011**, *Proc. Physiol. Soc.* 22, PC27.
140. Leuner, B.; Caponiti, J.M.; Gould, E. Oxytocin stimulates adult neurogenesis even under conditions of stress and elevated glucocorticoids. *Hippocampus*, **2012**, *22*, 861-868.
141. Bakos, J.; Strbak, V.; Paulikova, H.; Krajnakova, L.; Lestanova, Z.; Bacova, Z. Oxytocin receptor ligands induce changes in cytoskeleton in neuroblastoma cells. *J.Mol. Neurosci.*, **2013**. Jan 20. [Epub ahead of print].
142. Bales, K.L.; Boone, E.; Epperson, P.; Hoffman, G.; Carter, C.S. Are behavioral effects of early experience mediated by oxytocin? *Front. Psychiatry*, **2011**, *2*, 24.
143. Murgatroyd, C.A.; Nephew, B.C. Effects of early life social stress on maternal behavior and neuroendocrinology. *Psychoneuroendocrinology*, **2013**, *38*, 219-28.
144. Bales, K.L.; Lewis-Reese, A.D.; Pfeifer, L.A.; Kramer, K.M.; Carter, C.S. Early experience affects the traits of monogamy in a sexually dimorphic manner. *Dev. Psychobiol.*, **2007**, *49*(4), 335-342.

145. Bales, K.L.; Plotsky, P.M.; Young, L.J.; Lim, M.M.; Grotte, N.; Ferrer, E.; Carter, C.S. Neonatal oxytocin manipulations have long-lasting, sexually dimorphic effects on vasopressin receptors. *Neuroscience*, **2007**, *144*(1), 38-45.
146. Orelund, S.; Gustafsson-Ericson, L.; Nylander, I. Short- and long-term consequences of different early environmental conditions on central immunoreactive oxytocin and arginine vasopressin levels in male rats. *Neuropeptides*, **2010**, *44*, 391-398.
147. Branchi, I.; Curley, J.P.; D'Andrea, I.; Cirulli, F.; Champagne, F.A.; Alleva, E. Early interactions with mother and peers independently build adult social skills and shape BDNF and oxytocin receptor brain levels. *Psychoneuroendocrinology*, **2013**, *38*, 522-532.
148. Riem, M.M.; van Ijzendoorn, M.H.; Tops, M.; Boksem, M.A.; Rombouts, S.A.; Bakermans-Kranenburg, M.J. Oxytocin effects on complex brain networks are moderated by experiences of maternal love withdrawal. *Eur. Neuropsychopharmacol.*, **2013**, Feb 27. xxxxxx
149. Feldman, R.; Gordon, I.; Influs, M.; Gutbir, T.; Ebstein, R.P. Parental oxytocin and early caregiving jointly shape children's oxytocin response and social reciprocity. *Neuropsychopharmacology*, **2013**, xxxx
150. Huffmeijer, R.; van Ijzendoorn, M.H.; Bakermans-Kranenburg, M.J. Ageing and oxytocin: a call for extending human oxytocin research to ageing populations-a mini-review. *Gerontology*, **2013**, *59*, 32-39.
151. Domes, G.; Heinrichs, M.; Kumbier, E.; Grossmann, A.; Hauenstein, K.; Herpertz, S.C. effects of intranasal oxytocin on the neural basis of face processing in autism spectrum disorder. *Biol. Psychiat.*, **2013**, xxxx
152. Macdonald, K.; Feifel, D. Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders. *Front. Neurosci.*, **2013**, *7*, 35.
153. Rault, J.L.; Carte, C.S.; Garner, J.P.; Marchant-Forde, J.N.; Richert, B.T.; Lay, D.C. Jr. Repeated intranasal oxytocin administration in early life dysregulates the HPA axis and alters social behavior. *Physiol. Behav.* **2013**, *112-113C*, 40-48.
154. Hirose, T.; Kikuchi, M.; Higashida, H.; Okumura, E.; Ueno, S.; Shitamichi, K.; Yoshimura, Y.; Munesue, T.; Tsubokawa, T.; Haruta, Y.; Nakatani, H.; Hashimoto, T.; Minabe, Y. Oxytocin attenuates feelings of hostility depending on emotional context and individuals' characteristics. *Sci. Rep.*, **2012**, *2*, 384.
155. Bartz, J.A.; Zaki, J.; Ochsner, K.N.; Bolger, N.; Kolevzon, A.; Ludwig, N.; Lydon, J.E. Effects of oxytocin on recollections of maternal care and closeness. *Proc. Natl. Acad. Sci. U S A.*, **2010**, *107*, 21371-21375.
156. Salmina, A.B.; Shul'man, V.A.; Nikulina, S.Y.; Trufanova, L.V.; Fursov, A.A.; But'yanov, P.A.; Kuskaev, A.P.; Bol'shakova, E.V.; Kotlovskii, M.Y. Apoptosis of leukocytes as a marker of neutrophil-endotheliocyte interaction in coronary heart disease. *Bull. Exp. Biol. Med.*, **2007**, *144*, 39-41.
157. Wagner, G.K.; Black, S.; Guse, A.H.; Potter, B.V. First enzymatic synthesis of an N1-cyclised cADPR (cyclic-ADP ribose) analogue with a hypoxanthine partial structure: discovery of a membrane permeant cADPR agonist. *Chem. Commun. (Camb.)*, **2003**, *15*, 1944-1945.
158. Gu, X.; Yang, Z.; Zhang, L.; Kunerth, S.; Fliegert, R.; Weber, K.; Guse, A.H.; Zhang, L. Synthesis and biological evaluation of novel membrane-permeant cyclic ADP-ribose mimics: N1-[(5"-O-

- phosphorylethoxy)methyl]-5'-O-phosphorylinosine 5',5''-cyclicpyrophosphate (cIDPRE) and 8-substituted derivatives. *J. Med. Chem.*, **2004**, *47*, 5674-5682.
159. Lee, H.C.; Munshi, C.; Graeff, R. Structures and activities of cyclic ADP-ribose, NAADP and their metabolic enzymes. *Mol. Cell. Biochem.*, **1999**, *193*, 89-98.
160. Shuto, S.; Fukuoka, M.; Manikowsky, A.; Ueno, Y.; Nakano, T.; Kuroda, R.; Kuroda, H.; Matsuda, A. Total synthesis of cyclic ADP-carbocyclic-ribose, a stable mimic of Ca^{2+} -mobilizing second messenger cyclic ADP-ribose. *J. Am. Chem. Soc.*, **2001**, *123*, 8750-8759.
161. Kudoh, T.; Fukuoka, M.; Ichikawa, S.; Murayama, T.; Ogawa, Y.; Hashii, M.; Higashida, H.; Kunerth, S.; Weber, K.; Guse, A.H.; Potter, B.V.; Matsuda, A.; Shuto, S. Synthesis of stable and cell-type selective analogues of cyclic ADP-ribose, a Ca^{2+} -mobilizing second messenger. Structure-activity relationship of the N1-ribose moiety. *J. Am. Chem. Soc.*, **2005**, *127*, 8846-8855.
162. Sauve, A.A.; Schramm, V.L. Mechanism-based inhibitors of CD38: a mammalian cyclic ADP-ribose synthetase. *Biochemistry*, **2002**, *41*, 8455-8463.
163. Wall, K.A.; Klis, M.; Kornet, J.; Coyle, D.; Amé, J.C.; Jacobson, M.K.; Slama, J.T. Inhibition of the intrinsic NAD^+ glycohydrolase activity of CD38 by carbocyclic NAD analogues. *Biochem. J.*, **1998**, *335*, 631-636.
164. Kim, U.H. Kidney ADP-ribosyl cyclase inhibitors as a therapeutic tool for diabetic nephropathy, In: Diabetic nephropathy, Dr. John Chan (Ed.); InTech, **2012**; pp.85-96.
165. Kwong, A.K.; Chen, Z.; Zhang, H.; Leung, F.P.; Lam, C.M.; Ting, K.Y.; Zhang, L.; Hao, Q.; Zhang, L.H.; Lee, H.C. Catalysis-based inhibitors of the calcium signaling function of CD38. *Biochemistry*, **2012**, *51*, 555-564.
166. Kellenberger, E.; Kuhn, I.; Schuber, F.; Muller-Steffner, H. Flavonoids as inhibitors of human CD38. *Bioorg. Med. Chem. Lett.*, **2011**, *21*, 3939-3942.
167. Zhao, Y.J.; Zhang, H.M.; Lam, C.M.; Hao, Q.; Lee, H.C. Cytosolic CD38 protein forms intact disulfides and is active in elevating intracellular cyclic ADP-ribose. *J. Biol. Chem.*, **2011**, *286*, 22170-22177.
168. Dong, M.; Si, Y.Q.; Sun, S.Y.; Pu, X.P.; Yang, Z.J.; Zhang, L.R.; Zhang, L.H.; Leung, F.P.; Lam, C.M.; Kwong, A.K.; Yue, J.; Zhou, Y.; Kriksunov, I.A.; Hao, Q.; Lee, H.C. Design, synthesis and biological characterization of novel inhibitors of CD38. *Org. Biomol. Chem.*, **2011**, *9*, 3246-3257.
169. Mehta K. Retinoid-Mediated Signaling and CD38 Expression. In: *Cyclic ADP-Ribose and NAADP*; Lee H.C. Ed.; Springer US, **2002**; pp 409-425.
170. Riebold, M.; Mankuta, D.; Lerer, E.; Israel, S.; Zhong, S.; Nemanov, L.; Monakhov, M.V.; Levi, S.; Yirmiya, N.; Yaari, M.; Malavasi, F.; Ebstein, R.P. All-trans retinoic acid upregulates reduced CD38 transcription in lymphoblastoid cell lines from Autism spectrum disorder. *Mol. Med.*, **2011**, *17*, 799-806.
171. Ebstein, R.P.; Mankuta, D.; Yirmiya, N.; Malavasi, F. Are retinoids potential therapeutic agents in disorders of social cognition including autism? *FEBS Lett.*, **2011**, *585*, 1529-1536.
172. Vilboux, T.; Ciccone, C.; Blancato, J.K.; Cox, G.F.; Deshpande, C.; Introne, W.J.; Gahl, W.A.; Smith, A.C.; Huizing, M. Molecular analysis of the Retinoic Acid Induced 1 gene (RAI1) in patients with suspected Smith-Magenis syndrome without the 17p11.2 deletion. *PLoS One*, **2011**, *6*, e22861.

- 1 173. Girirajan, S.; Elsea, S.H. Abnormal maternal behavior, altered sociability, and impaired serotonin metabolism
2 in Rai1-transgenic mice. *Mamm. Genome*, **2009**, *20*, 247-255.
- 3 174. Carmona-Mora, P.; Walz, K. Retinoic Acid Induced 1, RAI1: A dosage sensitive gene related to
4 neurobehavioral alterations including autistic behavior. *Curr. Genomics*, **2010**, *11*, 607-617.
- 5 175. Cai, L.; Yan, X.B.; Chen, X.N.; Meng, Q.Y.; Zhou, J.N. Chronic all-trans retinoic acid administration induced
6 hyperactivity of HPA axis and behavioral changes in young rats. *Eur. Neuropsychopharmacol.*, **2010**, *20*, 839-47.
- 7 176. Shearer, K.D.; Fragoso, Y.D.; Clagett-Dame, M.; McCaffery, P.J. Astrocytes as a regulated source of retinoic
8 acid for the brain. *Glia*, **2012**, *60*, 1964-1976.
- 9 177. Matsuzaki, M.; Matsushita, H.; Tomizawa, K.; Matsui, H. Oxytocin: a therapeutic target for mental disorders. *J.*
10 *Physiol. Sci.*, **2012**, *62*, 441-444.
- 11 178. Salmina, A.B.; Okuneva, O.S.; Mikhutkina, S.V.; Malinovskaya, N.A.; Morgun, A.V.; Zyкова, L.D.; Yudin,
12 G.V.; Laletin, D.V.; Fursov, M.A.; Frolova, O.V.; Tagaeva, G.A.; Bolshakova, E.V. Perinatal hypoxic-ischemic
13 brain injury affects the glutamatergic signal transduction coupled with neuronal ADP-ribosyl cyclase activity.
14 *Bull. Exp. Bio.l Med.*, **2011**, *150*, 583-586.
- 15 179. Kou, W.; Banerjee, S.; Eudy, J.; Smith, L.M.; Persidsky, R.; Borgmann, K.; Wu, L.; Sakhuja, N.; Deshpande,
16 M.S.; Walseth, T.F.; Ghorpade, A. CD38 regulation in activated astrocytes: implications for neuroinflammation
17 and HIV-1 brain infection. *J. Neurosci. Res.*, **2009**, *87*, 2326-2339.
- 18 180. Choe, C.U.; Lardong, K.; Gelderblom, M.; Ludewig, P.; Leypoldt, F.; Koch-Nolte, F.; Gerloff, C.; Magnus, T.
19 CD38 exacerbates focal cytokine production, postischemic inflammation and brain injury after focal cerebral
20 ischemia. *PLoS On.*, **2011**, *6*, e19046.
- 21 181. Higashida, H.; Yokoyama, S.; Kikuchi, M.; Munesue, T. CD38 and its role in oxytocin secretion and social
22 behavior. *Horm. Behav.*, **2012**, *61*, 351-358.
- 23 182. Higashida, H. Biological basis for social recognition: CD38 controls oxytocin secretion. *Tanpakushitsu*
24 *Kakusan Koso.*, **2007**, *52*, 1832-1839.

Figure legends:

Fig.1. CD38-controlled mechanisms in the regulation of social behavior. A schematic representation of a key role of CD38 in different social behavior outputs by molecular pathways of oxytocin secretion, including NAD⁺ and NADP transformation, cyclic ADP-ribose formation, and Ca²⁺ release from ryanodine receptors.

Fig. 2. Pathophysiology of CD38-controlled social behavior: novel molecular targets for pharmacological amelioration.

HEALTHY

Normal
CD38 gene expression

CD38/ADP-ribosyl cyclase

OT receptors

PKC activation

cADPR formation

Ca²⁺ -mobilization

OT release ↑

OT
level

AVP

Autoregulation

Parental behavior
Pair bonding
Social recognition
Cognitive function
Anxiety
Emotional statement

PATHOLOGY

CD38 gene deletion (mice)
CD38 gene mutation (human)

CD38/ADP-
ribosyl cyclase

cADPR formation

Ca²⁺ -mobilization

OT release ↓

OT ↓

AVP

Abnormal parental behavior (mice)
Impairment in social recognition and
social memory (mice)
ASD's behaviour (human)

PATHOLOGY TREATMENT

infusion of lentiviral vectors
carrying human CD38 (lenti-CD38)
(mice)

Exogenous OT:

- injection (mice),
- nasal OT spray (human,
personal dependent)

AVP

OT ↑

Improve parental behavior (mice)
Rescue deficit of social recognition
and social memory (mice)
Reduce anxiety, promote eye-eye
contact, increase trust (human,
specially ASD patients)

GENETIC

CELLULAR LEVEL

BEHAVIOUR